New combo therapy may help more liver cancer patients qualify for transplant

NCT ID NCT07059494

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Nov 05, 2025 · Last updated Jun 15, 2026 · Updated 40 times

Summary

This study tests whether combining two drugs (atezolizumab and bevacizumab) with a type of internal radiation (Y-90) can shrink liver tumors enough for patients to become eligible for a liver transplant. About 40 adults with hepatocellular carcinoma (HCC) will receive this combination before transplant. The goal is to see if the treatment helps control the disease and improves chances of getting a transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

Contact

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA